Balanced news tone
News Sentiment
HIK sentiment intelligence
Hikma Pharmaceuticals PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+2.3% over one week, +7.0% over four weeks, trend inactive, and near fair-value range.
What's Behind Hikma Pharmaceuticals' (LSE:HIK) New UK Office Push To Support NHS Supply?
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
What's Behind Hikma Pharmaceuticals' (LSE:HIK) New UK Office Push To Support NHS Supply?
- Tone
- Neutral 50/100
- Event
- Macro sensitivity
- Published
- 16 Jul 2026 06:48
- Source
- Kalkine Media
Hikma Cancels More Shares as $250m Buyback Passes 10 Million Mark
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 14 Jul 2026 09:55
- Source
- The Globe and Mail
Could Hikma Pharmaceuticals (LSE:HIK) Be The Generics Story London Is Watching?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 09:00
- Source
- Kalkine Media
Hikma Pharmaceuticals PLC highlights its generics and injectables strength
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 07:48
- Source
- Ad Hoc News
Hikma Pharmaceuticals PLC outlines growth ambitions as a global generics supplier
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 Jul 2026 06:29
- Source
- Ad Hoc News
Enterprise value to EBITDA forward of Hikma Pharmaceuticals Plc – LSE:HIK
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 21:35
- Source
- TradingView
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Barchart.com
Why Are AstraZeneca, GSK and Hikma Lifting FTSE 100 Focus?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- Kalkine Media
Hikma Pharmaceuticals PLC stock (GB00B128J450): earnings momentum and US injectables footprint in fo
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 May 2026 07:00
- Source
- Ad Hoc News
How The Hikma Pharmaceuticals (LSE:HIK) Narrative Is Shifting After Analyst Valuation Resets
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 18 May 2026 07:00
- Source
- Market source
Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 11 May 2026 07:00
- Source
- Ad Hoc News
Independent Chairman of Hikma Pharmaceuticals Victoria Hull Buys 241% More Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 May 2026 07:00
- Source
- simplywall.st
How The Investment Story On Hikma Pharmaceuticals (LSE:HIK) Is Shifting With New Targets And News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Apr 2026 07:00
- Source
- Market source
How The Hikma Pharmaceuticals (LSE:HIK) Narrative Is Shifting As Analyst Targets Reset
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 20 Mar 2026 07:00
- Source
- Market source
How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 05 Mar 2026 08:00
- Source
- Market source
Hikma Pharma tumbles on softer guidance as buyback fails to soften pill
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 26 Feb 2026 08:00
- Source
- Market source
Hikma’s shares plummet after guidance cut
- Tone
- Negative 34/100
- Event
- Guidance
- Published
- 26 Feb 2026 08:00
- Source
- Investors' Chronicle
Hikma Pharmaceuticals PLC (LON:HIK) is largely controlled by institutional shareholders who own 59% of the company
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Feb 2026 08:00
- Source
- simplywall.st
Hikma Pharmaceuticals PLC (HIK.L) Stock Analysis: Unraveling a 41.93% Potential Upside with Strong Buy Ratings
- Tone
- Positive 95/100
- Event
- Market update
- Published
- 02 Feb 2026 08:00
- Source
- DirectorsTalk Interviews
Hikma Pharmaceuticals PLC (LON:HIK) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jan 2026 08:00
- Source
- simplywall.st
Investors in Hikma Pharmaceuticals (LON:HIK) have unfortunately lost 33% over the last five years
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Dec 2025 08:00
- Source
- simplywall.st
UK's Hikma CEO steps down, chairman takes helm until successor appointed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Dec 2025 08:00
- Source
- Reuters
Market Cool On Hikma Pharmaceuticals PLC's (LON:HIK) Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Dec 2025 08:00
- Source
- simplywall.st
Hikma Pharmaceuticals PLC (HIK) Stock Price Quote Today & Current Price Chart
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Nov 2025 18:14
- Source
- Capital.com
Hikma Pharmaceuticals: a quality compounder waiting for a catalyst
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jul 2025 07:00
- Source
- The Armchair Trader